Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug may help elderly MG patients ditch harmful steroids

NCT ID NCT07072988

Recruiting now Disease control Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study looks at whether efgartigimod, a drug that lowers harmful antibodies, can help elderly patients with generalized myasthenia gravis reduce their steroid use. Steroids often cause serious side effects in older adults. The study will follow 50 patients for 12 months to see if switching to efgartigimod improves muscle strength, quality of life, and overall health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
efgartigimod
What this could lead to
If successful, this could show that efgartigimod helps elderly MG patients reduce their steroid dose, leading to fewer side effects and better quality of life.
What could go wrong
This is a small, early-phase study with only 50 participants, so results may not apply to all patients. Efgartigimod may not work as well in real-world settings as in controlled trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS, GENERALIZED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYASTHENIA GRAVIS, GENERALIZED

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU de Nice

    RECRUITING

    Nice, Alpes-Maritimes, 06000, France

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.